MAIA Biotechnology, Inc.
Wednesday, June 05, 2024
Oncology
Company Presentation Theater 1
MAIA is an immuno-oncology company focused on the development and commercialization of potential first-in-class drugs that are intended to meaningfully improve and extend the lives of people with hard-to-treat cancers. We are exploring a new science for cancer therapy utilizing a novel dual mechanism of action: telomere targeting and immunogenicity. Our lead program is THIO, a first-in-class anticancer agent in clinical development for the treatment of Non-Small Cell Lung Cancer (NSCLC) in patients with telomerase-positive cancer cells.
Company Website:
https://maiabiotech.com/
Lead Product in Development:
THIO
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Exchange
NYSE American
Ticker
MAIA
Company HQ City
Chicago
Company HQ State
Illinois
Company HQ Country
United States
CEO/Top Company Official
Vlad Vitoc
Development Phase of Primary Product
Phase II
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())